MX2023006899A - Mutaciones ortogonales para heterodimerización. - Google Patents
Mutaciones ortogonales para heterodimerización.Info
- Publication number
- MX2023006899A MX2023006899A MX2023006899A MX2023006899A MX2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A
- Authority
- MX
- Mexico
- Prior art keywords
- heterodimerization
- orthogonal mutations
- domains
- mutations
- orthogonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123915P | 2020-12-10 | 2020-12-10 | |
| PCT/US2021/062951 WO2022125986A1 (en) | 2020-12-10 | 2021-12-10 | Orthogonal mutations for heterodimerization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006899A true MX2023006899A (es) | 2023-09-04 |
Family
ID=81974005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006899A MX2023006899A (es) | 2020-12-10 | 2021-12-10 | Mutaciones ortogonales para heterodimerización. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12312418B2 (https=) |
| EP (1) | EP4259194A4 (https=) |
| JP (1) | JP2024500354A (https=) |
| KR (1) | KR20230118612A (https=) |
| CN (1) | CN116867514A (https=) |
| AU (1) | AU2021397322A1 (https=) |
| CA (1) | CA3207821A1 (https=) |
| IL (1) | IL303518A (https=) |
| MX (1) | MX2023006899A (https=) |
| WO (1) | WO2022125986A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JP6385357B2 (ja) * | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| HK1220465A1 (zh) * | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| WO2016130516A1 (en) * | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
| US10696722B2 (en) * | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| CN110177805B (zh) * | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| JP7438942B2 (ja) * | 2017-10-30 | 2024-02-27 | エフ． ホフマン－ラ ロシュ アーゲー | 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法 |
| US20210163594A1 (en) * | 2018-04-17 | 2021-06-03 | Invenra Inc. | Binding molecules |
| KR102870868B1 (ko) * | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP7812230B2 (ja) * | 2019-04-25 | 2026-02-09 | エフ． ホフマン－ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| AU2021224883A1 (en) * | 2020-02-20 | 2022-09-29 | Invenra Inc. | Bispecific GD2 and B7H2 binding molecules and methods of use |
-
2021
- 2021-12-10 CA CA3207821A patent/CA3207821A1/en active Pending
- 2021-12-10 MX MX2023006899A patent/MX2023006899A/es unknown
- 2021-12-10 KR KR1020237022864A patent/KR20230118612A/ko active Pending
- 2021-12-10 CN CN202180091688.7A patent/CN116867514A/zh active Pending
- 2021-12-10 US US17/548,375 patent/US12312418B2/en active Active
- 2021-12-10 WO PCT/US2021/062951 patent/WO2022125986A1/en not_active Ceased
- 2021-12-10 AU AU2021397322A patent/AU2021397322A1/en active Pending
- 2021-12-10 JP JP2023535392A patent/JP2024500354A/ja active Pending
- 2021-12-10 IL IL303518A patent/IL303518A/en unknown
- 2021-12-10 EP EP21904522.6A patent/EP4259194A4/en active Pending
-
2025
- 2025-04-25 US US19/190,527 patent/US20260078202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021397322A9 (en) | 2024-06-20 |
| WO2022125986A1 (en) | 2022-06-16 |
| AU2021397322A1 (en) | 2023-07-06 |
| KR20230118612A (ko) | 2023-08-11 |
| EP4259194A1 (en) | 2023-10-18 |
| JP2024500354A (ja) | 2024-01-09 |
| US20260078202A1 (en) | 2026-03-19 |
| US20220363782A1 (en) | 2022-11-17 |
| CN116867514A (zh) | 2023-10-10 |
| IL303518A (en) | 2023-08-01 |
| EP4259194A4 (en) | 2025-03-19 |
| US12312418B2 (en) | 2025-05-27 |
| CA3207821A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003127A1 (es) | Anticuerpos bispecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| CL2018002046A1 (es) | Constructos de anticuerpo biespecíficos que se ligan a células t. | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| PY1888702A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
| IL305736A (en) | Heterodimeric antibodies that bind cd3 and cldn6 | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| MX2023006899A (es) | Mutaciones ortogonales para heterodimerización. | |
| MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
| PH12021550096A1 (en) | Compositions of fcrn antibodies and methods of use thereof | |
| AR128031A1 (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
| ECSP22041860A (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| CO2024000024A2 (es) | Moléculas de unión a gpc3 | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| JOP20250298A1 (ar) | تركيبات جسم مضاد لإنتيجرين α4β7 وطرق استخدامها | |
| BR112021020873A2 (pt) | Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3 | |
| PT4274851T (pt) | Anticorpos monoclonais anti-gprc5d e utilizações destes | |
| PE20200487A1 (es) | Proteinas de union al antigeno anti-jagged1 |